This article is for psychiatrists, primary care providers, acute care hospitals, and community mental health centers caring for our members
Intravenous ketamine and intranasal esketamine share the same medical necessity criteria for treatment-resistant depression, found in our medical policy 087. For that reason, you can use an approval for one drug/procedure for either treatment during the approval period without requesting a new prior authorization. Here are some tips to help you request authorization and bill for services:
When you are |
Please |
---|---|
Requesting authorizations for either intravenous ketamine or intranasal esketamine |
|
Billing for the service |
|
MPC072023-1F-1-ART